Cancer, regenerative failure, and the search for longevity biomarkers
20th October 2026
In episode #412, Peter Attia welcomes back oncologist and Pulitzer Prize-winning author Siddhartha Mukherjee, fifteen years after The Emperor of All Maladies, to review what has changed in cancer science: the contributions of genetics, environmental exposures, random mutations and inflammation to risk, the emerging role of hyperinsulinemia and metabolism, and why early detection remains so difficult, particularly in pancreatic cancer. The conversation then broadens to what Mukherjee calls regenerative failure - the declining ability of tissues to repair and replenish themselves with age - and asks whether longevity should be approached less as preventing individual diseases and more as preserving regenerative capacity.
Key takeaways:
- Treatment has moved - immunotherapy, CAR T cell therapy and targeted drugs such as KRAS inhibitors - while prevention and early detection have moved slower, and pancreatic cancer shows the gap most clearly
- Regenerative failure reframes ageing itself: the same loss of repair capacity may sit behind conditions as different as cancer and osteoarthritis
- Chemoprevention, metabolic interventions and AI are presented as directions to test, and the episode closes on what it would take to build meaningful biomarkers of longevity - none of which exists as a validated measure today
Hype check: Proven - the state of cancer treatment and detection as reviewed by two practising physicians; no new trial data is presented. Promising - regenerative failure as a unifying frame, and chemoprevention, metabolic and AI approaches as research directions. Marketing - none in the source; an expert conversation is orientation, not evidence that any screening or intervention discussed extends healthspan.